AstraZeneca (AZN) announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.The nod i ...